Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.

ABSTRACT:

Background

The evidence regarding triple oral combination therapy for patients with pulmonary arterial hypertension (PAH) is scarce. This study was performed to investigate the effectiveness and safety of triple oral combination therapy with macitentan, riociguat, and selexipag.

Methods

Among consecutive patients with PAH who were referred to our hospital from 2009 to 2020, those who underwent triple oral combination therapy using macitentan, riociguat, and selexipag were retrospectively analyzed. Hemodynamic and echocardiographic assessments and Kaplan-Meier analyses of all-cause death and initiation of prostacyclin infusion were conducted.

Results

Twenty-six patients underwent this combination therapy. These patients were predominantly female (73.1%) with a median a

SUBMITTER: Momoi M 

PROVIDER: S-EPMC7919213 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature